The drugmaker Erasca said Monday that its RAS-targeting pill shrank tumors in 40% of patients with advanced pancreatic cancer and 62% of patients with advanced non-small cell lung cancer, results that the company said exceeded its expectations.  The new data, collected from studies done in the U.S. and China, are still preliminary.
However, Erasca said the clinical benefit and tolerability of its drug, called ERAS-0015, compared favorably to daraxonrasib, a similar RAS-targeting drug from Revolution Medicines that recently showed a doubling of overall survival in patients with advanced pancreatic cancer.  “I’m excited about both datasets, but I think lung is more definitive at this point. The pancreatic results are maturing, but are very, very promising,” Erasca CEO Jonathan Lim told STAT.
“All options are on the table.”  Continue to STAT+ to read the full story...
Erasca announced early clinical activity for ERAS-0015, an oral agent that targets RAS, reporting tumor shrinkage rates in two advanced cancer populations.
The company compared these results to outcomes reported with another RAS-directed agent, daraxonrasib.
The reported findings derive from preliminary studies conducted in the United States and China.
The source does not provide formal trial design details such as phase, randomization, or sample size.
Erasca stated that ERAS-0015’s clinical benefit and tolerability compared favorably with data for daraxonrasib, a RAS inhibitor recently associated with improved overall survival in advanced pancreatic cancer.
The source emphasizes that the data are preliminary and maturing.
Specific methodological details, safety event rates, and quantitative survival outcomes were not reported.